Cerus Endovascular secures £600,000 for device to treat brain aneurysms


21 May 2013

Cerus Endovascular Ltd has secured  £600,000 investment from The North West Fund for Biomedical to further develop its implantable medical device for treating intracranial aneurysms.

The company is currently headquartered in Oxford but will soon move to Liverpool Science Park. The funding, which was part of a £1.5m investment round, will be used to help initiate product development and to fund more in-depth clinical trials leading to CE marking approval.

J Todd Derbin, executive chairman of Cerus Endovascular, said: “We believe our device represents the next generation in the minimally invasive treatment of neurovascular diseases, particularly intracranial aneurysms.

“We’re delighted to be working with SPARK Impact and The North West Fund for Biomedical. The investment means we can further develop our technology, which addresses unmet clinical needs in the interventional neuroradiology, cardiovascular, urology and gastroenterology markets.”

Dr Penny Attridge, senior investment director at SPARK Impact and manager of The North West Fund for Biomedical, said: “We are delighted to have Cerus Endovascular on board and to make this investment in a high quality service which is an asset to the North West and to SPARK’s biomedical portfolio.”

Cerus Endovascular Ltd is The North West Fund for Biomedical’s 52nd investment to date and 37th company to be supported by The Fund.


To top